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Purpose: To investigate the immunomodulatory and antitumor activities of ligustilide (LIG) extracted 
from Angelica sinensis in mice. 
Methods: Normal and tumor-bearing Institute of Cancer Research (ICR) mice were treated p.o. with LIG 
(5, 20 and 80 mg/kg/day) for 7 days. In normal ICR mice, phagocytosis of peritoneal macrophages and 
serum hemolysin concentration were assessed by chicken red blood cell ingestion test and quantitative 
hemolysis of sheep red blood cells assay, respectively. Lymphocyte proliferation was determined by 3-
(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) method. Both cytotoxic T 
lymphocyte (CTL) and natural killer (NK) cell activities were evaluated by lactate-dehydrogenase-
release assay. H22 ascites tumor cells were inoculated subcutaneously into ICR mice, followed by the 
determination of antitumor activity of LIG in the H22-bearing mice.  
Results: LIG significantly increased thymus and spleen index, macrophage phagocytosis, serum 
hemolysin concentration, spleen lymphocyte proliferation and CTL and NK cell activities in normal ICR 
mice, but inhibited the growth of transplantable H22 hepatoma. The effect was dose-related but not in a 
linear fashion. A dose of 20 mg/kg dose was more effective than 5 and 80 mg/kg doses.  
Conclusion: These results suggest that LIG at 20 mg/kg has a highly boosted the immune system and 
tumor inhibition. 
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Cancer is a major enemy threatening man’s 
being. Common approaches for treating 
cancer include surgery [1], chemotherapy [2], 
radiotherapy [3] and gene therapy [4].These 
modes usually come with side-effects. 
Hence, to find good cures and medicines has 
become increasingly become a major 
challemge to scientists. Immunomodulating 
agents can enhance or potentiate the host 
immune response against tumor without 
direct cytotoxicity to cancer cells [5].  
 
In China, herbal remedies (i.e., specified 
mixtures of dried plant materials) have been 
utilized empirically. Chinese traditional 
medicines, as alternative cancer therapies, 
have recently attracted a great deal of 
attention due to their low toxicity [6,7]. Radix 
Angelicae Sinensis, (RAS) commonly known 
as “dong quai”, is highly regarded in Chinese 
traditional medicine [8]. The major 
components of plant are classified into 
essential oil and water-soluble substances 
[9]. The former is believed to be its main 
pharmacological active components [10]. 
However, the essential oil consists of at least 
sixty-seven constituents, most of which are a 
great variety of lactones [9]. It has been 
reported that the total Angelica sinensis 
lactones (ASL) could significantly enhance 
mouse cellular immune function in vitro [11]. 
However, due to the complexity of the total 
ASL, it is unclear which components in ASL 
play a vital role in affecting the host immune 
function. In addition, the mechanisms of 
immunomodulatory action of ASL are not fully 
understood.  
 
Ligustilide (LIG), as the main component of 
ASL [12], has been shown to be effective in 
many pathological conditions such as 
cerebral ischemic damage [13], primary 
dysmenorrhoea [14] and Alzheimer's disease 
[15]. However, the immunomodulatory and 
antitumor effects of LIG have not been 
reported yet. In the present work, the 
immunomodulatory effects of LIG, including 
non-specific, humoral and cellular immunity, 
were investigated in normal ICR mice. The 
antitumor activity of LIG was also studied in 




Preparation of LIG  
 
Radix Angelicae Sinensis was purchased 
from the Danggui Cultivating Base of Good 
Agricultural Practice in Min Xian County, 
Gansu Province, China. The plant sample 
was collected in October, 2006, and the 
voucher specimen (no. 20061023) was 
deposited at the herbarium of West China 
School of Pharmacy, Sichuan University, 
Chengdu, China. Its identity was confirmed 
by Dr. Wang Chenyuan (West China School 
of Pharmacy, Sichuan University, Chengdu, 
China). LIG was prepared by a well-
established procedure in our laboratory. 
Briefly, the essential oil of Angelica sinensis 
was extracted using a supercritical-CO2 fluid 
system (the granule size of plant material, 60 
mu; extraction temperature, 50 ℃; extraction 
pressure, 10 MPa; extraction time, 2 h). LIG 
was isolated from the oil by silica-gel column 
chromatography and identified by electron 
impact ionisation MS, 1H NMR and 13C NMR 
spectrometric techniques. The column was 
eluted with petroleum ether (bp, 60-90℃) and 
subsequently with petroleum ether-ethyl 
acetate (100:5). For chromatographic 
analyses, HPLC grade reagents and Alltima 
C18 column (5μm, 150mm×4.6 mm) were 
used.  LIG peak was detected at an UV 




Male ICR mice, weighing 20.0±2.0 g, were 
provided by the experimental animal 
institution (Academy of Medical Sciences, 
Sichuan, China), and housed under normal 
laboratory condition ( 22 ± 2 ℃, 12/12-h light-
dark cycle) with free access to standard 
rodent chow and water. The experimental 
protocol was approved by the Institutional 
Animal Ethics Committee of Sichuan 
University, Chengdu, China (approval ref no. 
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SCXK (Chuan) 2006-15), and followed the 
guidelines published by the National 
Institutes of Health [16].  
 
Effect of LIG on immune function in 
normal ICR mice 
 
The animals were randomly divided into four 
groups (n = 10): normal control group and 5, 
20, 80 mg/kg LIG-treated groups. LIG was 
diluted in 3 % Tween-80 and administered 
p.o. for 7 days once daily. The normal control 
group was administered volume-matched 
vehicle (0.1 ml/10 g).On day 8, all the 
animals were sacrificed by decapitation. The 
mice, thymus and spleen were weighed, and 
the thymus and spleen indices w expressed 
as the thymus and spleen weight relative to 
mouse body weight. 
 
Macrophage phagocytosis assay 
 
Phagocytosis in the mice was performed 
using the methods of Lin et al [17] with some 
modifications. The mice were injectedi.p. with 
1.0 ml 2 % soluble starch 3 days prior to 
sacrifice. On day 8, the mice were injected 
i.p. with 0.5 ml 5 % cock red blood cells 
(CRBC). Thirty minutes later, the mice were 
sacrificed by decapitation. The peritoneal 
macrophages were washed by Hank’s 
solution. After rubbing the abdomen, fluid 
from the abdominal cavity was collected to 
make two smears for each mouse. The 
smears were incubated at 37℃ for 30 min in 
a wet box, washed by physiological saline 
solution, and then stained by Wright-Giemsa 
staining after quick drying. The number of 
CRBC ingested by 100 macrophages was 
counted in an optical microscope and 
expressed as phagocytosis index (PI), as in 
Eq 1, while phagocytic efficiency index (PEI) 
was determined as in Eq 2. 
 
PI = N/M ……………………… (1) 
 
where N is the number of total ingested 
CRBC and M is the number of macrophage 
ingesting CRBC 
PEI (%) = M/Mt)100 …………………. (2) 
 
where M is the number of macrophage 
ingesting CRBC and Mt is the number of total 
macrophages. 
 
Hemolysis of sheep red blood cells (QHS) 
assay 
 
QHS assay was detected using the method 
described by Xu and Li [18]. In brief, 0.2 ml of 
20 % sheep red blood cells (SRBC) prepared 
in normal saline was injected into the 
animals, i.p., 4 days prior to the assay. On 
day 4 following immunization, the mice were 
bled and serum samples were diluted with 
normal saline to 1:500. A total of 1.0 ml 5 % 
SRBC and 1.0 ml 10 % guinea pig serum 
were mixed with 1.0 ml diluted serum and 
incubated for 30 min. After centrifugation at 
2000 rpm for 10 min, the absorbance of the 
supernatant fluid was measured using a 
spectrophotometer (GBC Cintra 10e UV-
visible spectrometer) at 540 nm. The 
blank/control (in duplicate) consisted of 1.0 
ml 5 % SRBC, 1.0 ml 10 % guinea pig serum 
and 1.0 ml saline solution. 
 
Mitogen-induced splenocyte proliferation 
 
After sacrificing them, the mice were 
sterilized in 75 % ethanol. The spleens were 
extirpated on a clean bench. Under germ-free 
condition, single spleen cell suspension was 
prepared in cold phosphate buffered saline 
(PBS) by forcing spleen fragments through a 
fine nylon mesh. After washing twice in PBS, 
the cells were then resuspended to a 
concentration of 1×106 cells/ml in RPMI 1640 
completely cultivated liquid (HyClone, USA), 
using low speed centrifugation (1000 rpm for 
5 min). 
 
Single spleen cell suspension (100 μl ) was 
placed in each well of a 96-well microplate 
and 100 μl concanavalin A (ConA, 10 mg/l) or 
lipopolysaccharides (LPS, 100 mg/l ) was 
added to each test well; RPMI1640 (100 μl) 
cultivated liquid was added to the control 
well. Following treatment in 5 % CO2–air 
mixture at 37 oC for 44 h, MTT (5 g/l, 10 μl) 
was added to each well and the plate 
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incubated for another 4 h. The supernatants 
were discarded. A total of 150 μl dimethyl 
sulfoxide was added to each well. The plate 
was then shaken until the crystals were 
dissolved. The absorbance, A570, was 
detected on a microplate reader (Bio-Rad, 
Model 550, USA)  
 
Assay of cytotoxic T lymphocyte (CTL) 
 
The assay for cytotoxic T lymphocyte (CTL) 
activity was performed as described 
previously [7,19] with some modification. The 
splenocytes from each mouse were 
sensitized in vitro with mitomycin C-treated 
P815 mastocytoma cells at a 
responder/sensitizer ratio of 50:1 in a 5 % 
CO2–air mixture at 37 oC for 5 days. For the 
preparation of mitomycin C-treated P815 
cells, cells (1×105 cells/ml) were incubated in 
the dark with mitomycin C at a concentration 
of 0.25 μg/ml for 30 min at 37 ℃, and then 
the cells were washed four times. Following 
the sensitization phase, cultured spleen cells 
were harvested and resuspended in RPMI 
1640 complete cultivated liquid, counted and 
diluted to 1×106 cells/ml for the determination 
of CTL activity. P815 cells (1×105 cells/ml) 
were co-cultured in duplicate with 100 μl 
splenic effector cells in a 96-well microplate 
(cell ratio of effector: target, 10:1). After 
incubating for 4 h at 37 ℃, the plate was 
centrifuged at 1000 rpm/min for 5 min and the 
supernatant for each well (50 µl) was 
transferred into another 96-well microplate; 
100 µl of lactic acid dehydrogenase substrate 
mixture was added to each well. After 3 min, 
50 µl of 1M HCl was added to each well to 
stop the reaction. Finally, a microtiter plate 
reader (Bio-Rad, Modal 550, USA) was used 
for the evaluation of changes in the 
absorbance at a wavelength of 490 nm. To 
determine the percentage of killed target 
cells, Eq 3 was applied.  
 
CTL cell activity (%) = (E－ －S)/(M S)×100 …….. (3)  
 
where E is the experimental release of LDH 
activity from target cells incubated in the 
presence of lymphocytes, M the maximum 
release of LDH activity determined by lysing 
the target cells with 1 % of NP-40, and S the 
spontaneous release of LDH activity from 
target cells incubated in the absence of 
lymphocytes. 
 
Assay of NK cells activity 
 
Single spleen cells suspension (1 × 106 
cells/ml, 100 μl) and target cells YAC-1 
(1×105 cells/ml, 100 μl) were placed in a 96-
well microplate (effect: target ratio, 10:1). The 
cells were incubated in a 5 % CO2–air 
mixture at 37 oC for 4 h. Lactate 
dehydrogenase (LDH) activity was measured 
as described above. 
 
Evaluation of antitumor activity 
 
H22 hepatoma cells were maintained in the 
peritoneal cavities of ICR mice provided by 
the experimental animal institution (Academy 
of Medical Sciences, Sichuan, China). 
 
H22 ascites tumor cells (about 5×106 /ml) were 
inoculated subcutaneously (s.c.) into ICR 
male mice. Tumor size was measured using 
a caliper across its longest diameter (a) and 
the second longest diameter (b), and its 
volume was calculated using Eq 4.  
 
V = 0.5ab2. ……………………………….. (4)  
 
Treatment of the tumors was started after 7 
days when the mice showed palpable tumors 
(minimal volume of 14 mm3). The inoculated 
mice were randomized into five groups: 5, 20, 
80 mg/kg LIG treatment groups, H22-bearing 
mice as negative control group and cisplatin-
treated mice as positive control group. Cis-
diaminodichloroplatin (DPP, 2 mg/kg) was 
given to positive control group every week. 
LIG was diluted in 3 % Tween-80 and 
administered p.o. once daily. In all cases, the 
tumors were measured every 3 days. 
Inhibition ratio (IR) was calculated using Eq 
5.  
 
IR (%) = {(A − B)/A} × 100,…………….. (5) 
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where A and B are the mean tumor volume of 
the negative control and treatment groups, 
respectively. All the mice were sacrificed after 
15 days of treatment, when the longest 
diameter of tumors of control group exceeded 
20 mm. 
 
Statistical analysis  
 
The results were expressed as mean ± 
standard deviation (SD). Statistical analysis 
was performed with SPSS 13.0. Analysis of 
variance was followed by Fisher’s least 
significant difference test. Differences were 




Effect of LIG on nonspecific immune 
function in normal ICR mice     
 
The purity of LIG was > 98 % based on the 
total peak area obtained by HPLC analysis in 
this study.As shown in Table 1, treatment 
with LIG (20 mg/kg) produced the highest 
number of thymus, and also yielded the 
greatest spleen index, phagocytosis index 
(PI) and phagocytic efficiency index (PEI); 5 
and 20 mg/kg doses caused a significant 
increase in the above parameters (p < 0.05 
and p < 0.001, respectively). Treatment with 
LIG (80 mg/kg) only slightly increased 
thymus, spleen index and macrophage 
phagocytosis, but no significant increase was 




Effect of LIG on humoral immune function 
in normal ICR mice 
 
Table 1 shows that treatment with LIG (20 
mg/kg) significantly increased hemolysin 
concentration in normal ICR mice (p < 0.05 ). 
LIG (5 or 80 mg/kg) also increased antibody 
concentration in mouse serum, but the 
difference (compared with control) was not 
significant (p>0.05).  
 
Effect of LIG on cellular immunity in 
normal ICR mice 
 
The effect of LIG on induced proliferation of 
splenic lymphocytes (induced by Con A or 
LPS) is shown in Table 2, Con A-induced T 
lymphocyte proliferation was significantly 
increased at all LIG dose levels of 5, 20, 80 
mg/kg (p < 0.001, p < 0.001,and p < 0.001, 
respectively), and the proliferation rate was 
19.2, 27.6 and 10.3 %, respectively. LPS- 
induced B lymphocyte proliferation was also 
significantly increased (p < 0.001) at all LIG 
dose levels at the proliferation rate 16.2, 21.9 
and 14.1%, respectively. 
 
Enhancement of proliferation of splenic 
lymphocytes by LIG suggests that this 
compound may also affect the generation of 
cell-mediated cytotoxic responses. To test 
this, we examined the effect of LIG on the 
production of antigen-specific cytotoxic T 
lymphocytes (CTLs). The cytolytic activity of 
effector cells against p815 target cells was 
determined by lactate dehydrogenase activity 
assay. CTL activity increased at all three LIG 
doses in normal ICR mice (p < 0.001), as 
shown in Figure 1A.  
 
Table 1: Effect of LIG on thymus and spleen indice, macrophage phagocytosis and serum hemolysin 







(mg/g) PEI (%) PI QHS A540 
Control 1.89±0.51 6.09±0.62 37.39±3.60 1.01 ± 0.06 0.403±0.075 
5 2.57±0.84* 7.12±0.87*  45.33±3.97** 1.07 ± 0.09* 0.481±0.069 
20 3.02±0.90** 7.78±0.76**   48.06±3.44** 1.13 ± 0.09** 0.510±0.057* 
80 2.29±0.88 6.70±1.58 38.72±3.00 1.04 ± 0.07 0.462±0.071 
* p< 0.05, ** p< 0.001, compared with control group 
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Table 2: Effects of LIG on spleen lymphocyte 
proliferation, CTL and NK activity in normal ICR 
mice (mean ± S.D, n=10) 
Group ( 
mg/kg/d) 





Control - - 
5 19.2 ±12.5** 16.2 ± 3.1** 
20 27.6 ± 14.1** 21.9 ± 5.8** 
80 10.3 ± 7.6* 14.1 ± 9.8** 
* p< 0.05, ** p< 0.001  compared with control group. 
 
     
Figure 1： Effect of LIG on (A) CLT and (B) NK cell 
activity in normal ICR mice; ** p < 0.001 compared 
with control group (mean ± S.D, n=10) 
  
To investigate the effect of LIG on the 
development of non-specific cytotoxic cells, 
the cytotoxic activity of NK cells was 
determined by LDH release assay using 
YAC-1 as target cells. The effect of LIG on 
the development of NK cell-mediated 
cytotoxicity was significantly different from the 
control at all three doses (p < 0.001), as 
Figure. 1B shows. 
   
Antitumor activity of LIG in H22-bearing 
mice 
 
As shown in Figure 2, LIG significantly 
inhibited the growth of mouse transplanted 
H22 hepatoma. After 15 days treatment, the 
tumor inhibitory rate was 17.1, 46.9 and 27.7 
% for LIG dose levels of 5, 20 and 80 mg/kg, 
respectively. LIG (20 mg/kg) exerted the 
highest inhibitory effect (46.9 %), close to that 






Figure 2: Antitumor activity of LIG in H22 tumor-
bearing ICR mice. Note: control group (■), 
80mg/kg LIG group (△), 5mg/kg LIG group (◆), 




The relationship between the occurrence, 
growth and decline of tumor and immune 
states is a major problem in tumor 
immunology. The discovery and identification 
of new antitumor drugs to potentiate immune 
function has become an important goal of 
research in immunopharmacology and 
oncotherapy. This study demonstrates the 
favorable immunomodulatory activity and 
antitumor effect of LIG, a phthalide derivative 
from Angelica sinensis. 
 
Protective immunity against tumor comprises 
of non-specific, humoral and cellular 
immunity. Enhancement of phagocyte 
function is applicable to therapy of cancer 
because phagocytes act as regulator and 
effector cells in the immune system and 
phagocytosis represents an indispensable 
step in the immunological defense system 
[20]. Humoral defence via antibody response 
is mediated by B cells and other immune 
cells involved in antigen processing and 
immunization. Antigen–antibody complex can 
counteract toxins and defend the infection 
induced by the pathogen. Cell-mediated 
immune defense is mediated specifically by T 
cells including cytotoxic T cells. T cells can 
kill tumors and produce many lymphocyte 
factors consisting of macrophage mobile 
factor, lymphotoxin, transfer factor and 
interferon, which can enhance macrophage 
phagocytosis and the capacity of killing target 
cells [21]. NK cells mediate the immediate 
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killing of tumor cells and play a primary role in 
regulating immune responses as well [22].  
 
In this study, we found that LIG significantly 
increased macrophage phagocytosis, 
hemolysin concentration, spleen lymphocyte 
proliferation, as well as CTL and NK cell 
activities in normal ICR mice, which suggests 
that LIG could enhance non-specific, humoral 
and cell-mediated immunity in normal mice. 
Based on this, it seems likely that LIG might 
have potential tumor therapeutic activity by 
enhancing the immune system.  
 
On examining the effect of LIG on the H22-
bearing ICR mice, it was found that LIG 
significantly inhibited the growth of mouse 
transplantable H22 hepatoma after treatment 
with LIG and the inhibitory effect of LIG (20 
mg/kg) was close to that of the positive 
control, DPP (2 mg/kg). 
 
The inhibitory effect of LIG on tumor growth 
as well as its immunomodulatory activity 
were dose-dependent, with the effect of the 
highest LIG (80 mg/kg) lower than that of the 
least dose (5mg/kg). Thus, 20mg/kg can be 
considered the optimum LIG dose to 
enhance host immune function and inhibit 
tumor growth in mice. It was reported that the 
key to regulating the immune function rests 
in the level of immune state in the body, not 
the level of dose. The immune level can be 
regulated in autoimmunity process and no 
effect was evident at higher doses above the 
limit. It was achieved by integral harmony 
function in which network of immune-





The present study, to the best of our 
knowledge, reports for the first time the 
immunomodulatory and antitumor activities 
of LIG. The findings indicate that the 
antitumor activity of LIG is due to the 
augmentation of immune responses against 
tumors. Thus, the compound is a potentially 
attractive drug candidate for cancer therapy, 
possibly by combining it with 
chemotherapeutic agents with a view to 
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